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Two facts in dialysis patients…
Jadoul M, Kidney Int ,2006, p1358 Foley RN, Am J Kidney Dis, 1998, S112
25=80
Coronary calcifications in dialysis patients:
• Very frequent (over 50%) and severe
• Early and more rapidly progressive 
Goodman WG, N Engl J Med, 2000, p1478
Relationship between 
• Cardiovascular mortality and mineral metabolism markers (P, Ca, and PTH)
Relationship between 
• Several mineral metabolism markers and VC
Relationship between 
• VC and cardiovascular mortality
Is it causal?
Bone health in CKD patient
(turnover versus volume versus mineralization)
Moorthi N, Kidney Int, 2013, p886
Bone turnover is associated with VC
London GM, J Am Soc Nephrol, 2008, p1827
Osteoporosis is associated with VC
This concept of Bone-Vascular axis is also suggested by basic research
Vervloet M, Kidney Int, 2017, p808
• FGF-23/Klotho
• Fetuin-A
• Matrix Gla protein







Still not fit for clinical purpose !
Matrix Gla Protein and Sclerostin
• Recent
• Clinical research with VC is active
• Potentially linked to future therapy
• Specific challenges in Clinical Chemistry
Matrix Gla protein (MGP)
• 11 kD protein, 84 amino acids
• Secreted by chondrocytes and vascular smooth muscle cells (VSMC)
• Act as a local calcification inhibitor 
 Directly inhibiting calcium precipitation and crystallization (fetuin A)
 Antagonizing BMP-2 which promote osteablastic differentiation of VSMC
• MGP knockout mice
 Extensive arterial and cartilage calcification
 Death within 2 months due to rupture of calcified aorta
Two post-translational modifications
• Carboxylation of glutamate residues
– Binding of Ca-ions and crystals 
• Phosphorylation of serine residues
– Function? Regulation of secretion of MGP into the extracellular 
matrix.
– Binding of MGP to sites of calcification 
Matrix Gla protein (MGP)
Carboxylation of glutamate residues 
is highly dependent on Vitamin K
Circulating MGP
Carboxylation and phosphorylation of MGP are not always fully exerted 
– Results in different MGP species in the circulation (ELISA, VitaK, Maastricht)
– Very different results according to species
– The first commercially available automate (IDS, Boldon, UK) measures the inactive 
form: dp-ucMGP
MGP and Vascular Calcification




• Adragao score for VC + FAV
All cause CV
• 160 HD
• Kauppila score for VC






• Not the same calcification scores
• Added value at the individual level to quantify or detect the 
calcifications ?
But Inactive MGP is representative of the 
vitamin K status
• Low vitamin K status in dialysis patients Cranenburg E, Thromb Haemostase, 2010, p811
MGP and anti-vitamin K in dialysis patients
Delanaye P, BMC Nephrol, 2014, p145
MGP and anti-vitamin K in dialysis patients
Delanaye P, Clin Chem Lab Med, 2015, pe191
Vitamin K and inactive MGP
•
Schlieper G, J Am Soc Nephrol, 2011, 22, 387-395
Westenfeld R, Am J kidney Dis, 2012, 59, 186-195
Caluwe R, NDT, 2014, p1385
N=448
Sclerostin and VC
• 22 kDa, produced by osteocytes and inhibitor of bone formation if 
lack of mechanical stimulation 
• Sclerostin is higher in CKD 
Pelletier S, 
Sclerostin and VC
• Sclerostin could be involved in VC 
• Anti-sclerostin antibody (romosozumab)
Delanaye P, Kidney Int, 2015, p1221
But the clinical results are highly discrepant…




Because we don’t know what we measure…
BM TE RD MSD
All
n=121
1209 [889] 698 [452] 157 [99] 32 [21]
All non-dialysis
n=82
984 [648] 629 [237] 154 [84] 36 [19]
Iohexol GFR > 60 
mL/min (group A)
n=50
904 [613] 609 [181] 156 [55] 36 [17]
Iohexol GFR < 60 
mL/min (group B)
n=32




1976 [1972] 1050 [788] 169 [195] 23 [16]
Median [IQR] concentrations of sclerostin. CKD: chronic kidney disease. All results expressed in pg/mL




















































































































Group A Group B Group C
Group A
Group A Group A
Group A Group A
Group B
Group B Group B
Group B Group B
Group C
Group C
Group C Group C
Delanaye P, 2017, submitted
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Group A Group B Group C Group A Group B Group C
Group A Group B Group C Group A Group B Group C
Group A: Iohexol GFR > 60 mL/min (n=50)
Group B: Iohexol GFR < 60 mL/min (n=32)
Group C: Dialysis patients (n=39)
Delanaye P, 2017, submitted
Bone Biomarkers and vascular calcifications
• Solid pathophysiological basis
• The exact role must still be defined: Detection? Quantification? Therapy effect?
• Focus on biomarkers with a potential therapeutic implication
• Need for improvements in measurements
• Still much work for clinicians and labs!
Thank you for your attention
